

New Biologically Active Marine Sesquiterpenoid and Steroid from the Okinawan Sponge of the Genus *Axinyssa*

Makoto IWASHIMA,^{a,1)} Ikuo TERADA,^a Kazuo IGUCHI,^{*,a} and Takao YAMORI^b

^a School of Life Science, Tokyo University of Pharmacy and Life Science; Horinouchi, Hachioji, Tokyo 192–0392, Japan; and ^b Cancer Chemotherapy Center, Japanese Foundation for Cancer Research; Kami-ikebukuro, Toshima-ku, Tokyo 170–8455, Japan. Received May 2, 2002; accepted June 3, 2002

A new bisabolane-type sesquiterpenoid, (*E*)-3-isocyanobisabolane-7,10-diene (1**), and a new epidioxysterane-type steroid, 9(11)-dehydroaxinysterol (**2**), were isolated from the Okinawan sponge of the genus *Axinyssa*. Their structures were elucidated based on the results of spectroscopic analysis and chemical conversion. Epidioxysterol **2** was found to show significant growth inhibitory effects against human cancer cell lines.**

Key words marine sponge; genus *Axinyssa*; bisabolane sesquiterpenoid; 5 α ,8 α -epidioxysterol


During the course of our investigations of biologically active chemical substances from the Okinawan invertebrates,^{2–4)} a bisabolane-type sesquiterpenoid (*E*)-3-isocyanobisabolane-7,10-diene (**1**) and an ergostane-type steroid 9(11)-dehydroaxinysterol (**2**) were newly isolated from a sponge of the genus *Axinyssa* along with known compounds such as axinysterol (**3**).⁵⁾ This paper describes the structural elucidation of these compounds, the lethal bioassay for brine shrimp⁶⁾ of **1**, and the growth inhibitory activity against human cancer cell lines⁷⁾ of **2**.

The isolation and purification were carried out as described in the Experimental section.


The molecular formula of **1** was found to be C₁₆H₂₅N by high-resolution electron impact MS (HR-EI-MS). All the carbons in **1** appeared in the ¹³C-NMR spectrum (Table 1). The distortionless enhancement by polarization transfer (DEPT) spectrum indicated four methyls, five *sp*³ methylenes, one *sp*³ methine, two *sp*² methines, one *sp*³ quaternary carbon, and three *sp*² quaternary carbons. Two of the quaternary carbon signals at δ 56.3 ($J_{\text{NC}}=5.5$ Hz) and 156.1 ($J_{\text{NC}}=5.5$ Hz) ppm in C₆D₆ were both observed as a triplet due to the coupling with ¹⁴N.⁸⁾ These findings together with the IR absorption at 2130 cm⁻¹ strongly suggest the presence of an isonitrile group (–NC) in **1**. The ¹H-NMR analysis showed the presence of three olefinic methyls at δ 1.45 (s), 1.61 (s), and 1.71 (s) ppm, one methyl group connected to quaternary carbon at δ 1.00 (t, $J=2.0$ Hz) ppm, and two olefinic protons at δ 5.14 (t, $J=7.1$ Hz) and 5.27 (t, $J=7.1$ Hz) ppm (Table 1). All the connections for each carbon–proton direct bonding were made from the analysis of ¹³C–¹H correlation spectroscopy (¹³C–¹H COSY). Partial structures

of **1**, as shown in Fig. 1, were deduced from ¹H–¹H correlation spectroscopy (¹H–¹H COSY).


The gross structure of **1** was established by the following heteronuclear multiple bond correlation (HMBC) analysis (Fig. 1). ¹H–¹³C long-range correlations observed from H-2 (CH₂) and H-4 (CH₂) to C-3, and from H-15 (CH₃) to C-2, C-3 and C-4, indicated the carbon–carbon connections around C-3. Correlations from H-8 (CH) to C-6, from H-9



(*E*)-3-isocyanobisabolane-7,10-diene (**1**)



9(11)-dehydroaxinysterol (**2**)





axinysterol (**3**)

Table 1. NMR Data of **1** in C₆D₆ (δ ppm)^{a)}

No.	¹³ C	¹ H	No.	¹³ C	¹ H
1	26.7	0.98 (dtd, 4.2, 11.4, 13.9), 1.35 (m)	9	27.4	2.78 (2H, t, 7.1)
2	38.4	1.49 (m), 1.54 (m)	10	123.7	5.27 (t, 7.1)
3	56.3 (t, 5.5) ^{b)}		11	131.3	
4	38.4	1.49 (m), 1.54 (m)	12	25.8	1.71 (3H, s)
5	26.7	0.98 (dtd, 4.2, 11.4, 13.9), 1.35 (m)	13	17.7	1.61 (3H, s)
6	44.7	1.57 (m)	14	14.6	1.45 (3H, s)
7	137.8		15	24.8	1.00 (3H, t, 2.0)
8	122.6	5.14 (t, 7.1)	16	156.1 (t, 5.5) ^{b)}	

a) ¹³C; 125 MHz. ¹H; 500 MHz, J in Hz. Assignments of the ¹³C and ¹H signals were based on HMQC. b) J_{NC} in Hz. Coupled to ¹⁴N observed as 1 : 1 : 1.⁶⁾

Fig. 1. Partial Structures and Important HMBC for **1**Fig. 2. Important NOE Correlations and *trans*-Diaxial Relationship between H-1, H-5, and H-6

(CH₂) to C-7, and from H-14 (CH₃) to C-7 and C-8 demonstrated the connections around C-7. Finally, correlations from H-9 (CH₂) to C-11, from H-10 (CH) to C-12 and C-13, and from H-12 (CH₃) and H-13 (CH₃) to C-10 and C-11, indicated the terminal structure of the side chain in **1**. These spectroscopic findings together with the unsaturation number (*U*=5) disclosed that compound **1** had the structure of a bisabolane-type sesquiterpenoid with an isonitrile moiety at C-3.^{8–10} This gross structure of **1** indicated that the molecule of **1** has a plane of symmetry across the C-3 and C-6 positions on the cyclohexane ring, and thus **1** is achiral and optically inactive; [α]_D²⁵ 0.0° (CHCl₃). However, the stereochemistry of the olefin moiety and the relative configuration between C-3 and C-6 must be determined.

Stereochemistry of the trisubstituted olefin between C-7 and C-8 was confirmed to be an *E* configuration by nuclear Overhauser effect (NOE) analysis, as shown in Fig. 2. The relative configuration between C-3 and C-6 was revealed by the combined analysis of NOESY and *J* values observed in ¹H-NMR spectrum. As shown in Fig. 2, NOE correlations between the methyl protons (H-15) at C-3 and one of the methylene protons at both C-1 (H-1a) and C-5 (H-5a) [δ 0.98 (dtd, *J*=4.2, 11.4, 13.9 Hz)] indicated that H-15, H-1a, and H-5a were directed to the same side of the cyclohexane ring. The ¹H–¹H large coupling constant (*J*=11.4 Hz) of the triplet signal of H-1a and H-5a demonstrated these protons to be axial and to couple with the adjacent axial protons (H-2, H-6 for H-1 and H-4, H-6 for H-5). These findings indicated H-6 to be axially directed to the opposite side of H-15, H-1a, and H-5a, and thus the side chain group at C-6 to be equatorially directed, as shown in Fig. 2. The structure of **1** was thus concluded to be (*E*)-3-isocyanobisabolane-7,10-diene.

The biological activity of **1** was examined to estimate the lethal concentration (LC₅₀) for brine shrimp,⁶ and compound **1** showed strong activity at LC₅₀ 0.1 μ g/ml. The other bioactivities for **1** are currently under investigation.

The molecular formula of compound **2**, C₂₈H₄₀O₃, was determined by HR-EI-MS analysis. IR, ¹H-, and ¹³C-NMR spectra of **2** were quite similar to those of axinysterol (**3**),⁵ which had the molecular formula C₂₈H₄₂O₃, suggesting **2** to

Table 2. NMR Data of **2** and **3** in CDCl₃ (δ ppm)

No.	2 ^a		3
	¹³ C (125 MHz)	¹ H (500 MHz, <i>J</i> in Hz)	
1	32.6	1.68 (m), 2.06 (m)	34.8
2	30.6	1.57 (m), 1.92 (m)	30.2
3	66.3	4.00 (tt, 5.1, 11.4)	66.6
4	36.1	1.92 (dd, 11.4, 13.7), 2.10 (m)	37.1
5	82.7		82.3
6	135.5	6.28 (d, 8.5)	135.4 ^{b)}
7	130.7	6.59 (d, 8.5)	130.8
8	78.3		79.5
9	142.6		51.2 (CH)
10	38.0		37.1
11	119.7	5.42 (dd, 1.9, 6.0)	20.7 (CH ₂) ^{c)}
12	41.2	2.08 (m), 2.26 (dd, 6.0, 17.0)	39.5
13	43.6		44.7
14	48.2	1.83 (dd, 8.2, 12.3)	51.8
15	20.9	1.57 (m), 1.68 (m)	23.5 ^{c)}
16	28.6	1.38 (m), 1.78 (m)	28.7 ^{c)}
17	55.8	1.37 (m)	56.3
18	12.9	0.73 (3H, s)	13.0
19	25.5	1.09 (3H, s)	18.3
20	39.7	2.05 (m)	39.6
21	20.5	1.00 (3H, d, 6.6)	20.69 ^{d)}
22	135.2	5.23 (dd, 7.8, 15.3)	135.5 ^{b)}
23	132.0	5.29 (dd, 6.7, 15.3)	132.0
24	43.6	2.71 (quint, 6.7)	43.7
25	149.7		149.8
26	108.9	4.69 (m), 4.70 (m)	109.0
27	20.6	1.67 (3H, s)	20.74 ^{d)}
28	18.8	1.08 (3H, d, 6.7)	18.9

^a Assignments of the ¹³C and ¹H signals were based on ¹³C–¹H COSY. ^b, ^c, ^d Values with the same subscript may be interchanged.




Fig. 3. Important NOE Correlations and Long-Range Coupling (Bold)

be a dehydro-congener of **3**. Differences between **2** and **3** were found in the NMR spectra, due to the presence of a new trisubstituted olefin at δ 5.42 (dd, *J*=1.9, 6.0 Hz) ppm in the ¹H-NMR, and at δ 119.7 (CH) and 142.6 (C) ppm in the ¹³C-NMR spectra of **2** (Table 2).

Two-dimensional NMR spectra [¹H–¹H COSY, ¹H-detected heteronuclear multiple quantum coherence (HMQC), and HMBC] indicated that this new double bond is located between the C-9 and C-11 positions. The relative configuration of **2** was determined based on the following evidence. NOESY analysis focused on the ring junctures of the steroidal skeleton confirmed that **2** has the same relative configuration as that of **3** (Fig. 3). The NOE correlation between H-14 and H-12 α , which showed long-range coupling (W-shape) with the angular methyl group (H-18) in the COSY spectrum, as shown in the bold lines in Fig. 3, exhibited the *trans* configuration between H-14 and H-18. The relative configuration of H-17 was assigned as an α orientation due to the NOE correlation between H-12 α and H-17. The α ori-




Chart 1

Table 3. Growth Inhibitory Activity (IC_{50}) of **2** against Human Cancer Cell Lines^{a)}

Origin of cancer	Cell line	IC_{50} ($\mu\text{g/ml}$)	Origin of cancer	Cell line	IC_{50} ($\mu\text{g/ml}$)
Breast	HBC-4	0.85	Colon	HCC2998	0.57
	BSY-1	0.60		KM-12	0.60
	HBC-5	0.96		HT-29	0.57
	MCF-7	0.36		HCT-15	0.75
	MDA-MB-231	1.26		HCT-116	0.48
Lung	NCI-H23	0.54	Ovary	OVCAR-3	0.19
	NCI-H226	0.63		OVCAR-4	0.60
	NCI-H522	0.57		OVCAR-5	0.54
	NCI-H460	0.81		OVCAR-8	0.22
	A549	0.96	CNS ^{b)}	SK-OV-3	0.81
	DMS273	0.54		U251	0.63
	DMS114	0.48		SF-268	1.02
	St-4	0.69		SF-295	0.75
Stomach	MKN1	0.42	SF-539	0.84	
	MKN7	0.48	SNB-75	2.16	
	MKN28	0.84	SNB-78	1.17	
	MKN45	0.54	Prostate	DU-145	0.54
	MKN74	0.54		PC-3	0.57
	Kidney	RXF-631L	0.72	Melanoma	LOX-IMVI
ACHN		0.51			

a) Each IC_{50} value was estimated from its GI_{50} value. b) CNS, central nervous system.

entation of the epidioxy group was determined by the NOE correlations between H-18 and H-7 (olefinic proton). The relative configuration of the angular methyl group at C-10 was indicated by the NOE correlation between H-6 (olefinic proton) and H-19, and the stereochemistry at C-3 was deduced from the J values of H-3 ($J=5.1, 11.4$ Hz). The stereochemistry of two chiral centers in the side chain was assigned by comparison of the ^{13}C -NMR data from C-20 to C-28 with those in **3** (Table 2). The chemical shift values of nine carbons in **2** were essentially identical to those of **3**.

The following chemical conversions⁵⁾ from **2** to the known diol **4**¹¹⁾ were carried out to establish the absolute configuration of **2**, as summarized in Chart 1. Catalytic hydrogenation

of **2** in the presence of 10% palladium on carbon in ethyl acetate gave **4** $\{[\alpha]_D^{25} + 13.3^\circ\}$. The authentic diol **4** $\{[\alpha]_D^{25} + 10.6^\circ\}$ was independently prepared from ergosterol in two steps with photosensitized oxidation,^{5,12)} in which the desired epidioxysterol **5** was obtained as a minor product, followed by catalytic hydrogenation. The spectral data of **4** derived from **2** were identical to those of authentic **4**, including the sign of its optical rotation value. These findings together with the spectral analysis confirmed the structure of this new sterol **2** to be 9(11)-dehydroaxinysterol.

The growth inhibitory properties of **2** against cancer cells were examined with a disease-oriented panel of 39 human cancer cell lines (HCC panel) in the Japanese Foundation for Cancer Research.⁷⁾ Compound **2** exhibited a strong growth inhibitory effect against some ovarian cancer cells such as OVCAR-3 at IC_{50} 0.19 $\mu\text{g/ml}$ ($\log GI_{50} -6.20$) and OVCAR-8 at IC_{50} 0.22 $\mu\text{g/ml}$ ($\log GI_{50} -6.14$), as shown in Table 3, and also indicated significant growth inhibition in 21 human cancer cell lines at less than 0.60 $\mu\text{g/ml}$. Estimation of its bioactivities is now underway, including *in vivo* bioassay.

Experimental

Optical rotations were measured with a JASCO DIP-370 automatic polarimeter. IR spectra were recorded with a Perkin-Elmer FT-IR 1600 spectrophotometer. NMR spectra were recorded with a Bruker DRX-500 and DPX-400 spectrometer (^1H , 500 and 400 MHz; ^{13}C , 125 and 100 MHz) in C_6D_6 for **1** and in CDCl_3 for **2**, respectively. Two-dimensional NMR spectra (^1H - ^1H COSY, ^{13}C - ^1H COSY, HMQC, HMBC, and NOESY) were measured using standard Bruker pulse sequences. Chemical shifts are given on a δ (ppm) scale with either CHCl_3 (^1H , 7.26 ppm; ^{13}C , 77.0 ppm) for CDCl_3 or C_6H_6 (^1H , 7.20 ppm; ^{13}C , 128.0 ppm) for C_6D_6 as the internal standard (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad). Mass spectra were recorded with a Micromass Auto Spec spectrometer. Reverse-phase ODS column chromatography was carried out on YMC S-50 gel (ODS-AM120-S50). Normal-phase flash column chromatography was performed on Merck silica gel 60 (230–400 mesh). Medium-pressure liquid chromatography (MPLC) was carried out with a Kusano KHLC-201-43 apparatus using a CIG prepack column (silica gel, CPS-HS-221-05, for normal phase and ODS silica gel, CPO-HS-221-20, for reverse phase). HPLC with a recycling loop was performed on a YMC-Pack SIL-06 column (silica gel, SH-043-5-06, normal phase) and a YMC-Pack ODS-AM column (ODS, SH-343-5AM, reverse phase).

Extraction and Isolation The sponge of the genus *Axinyssa* (order Halichondria, family Desmospongiae) was collected from a coral reef near Ishigaki Island, Okinawa Prefecture, Japan in June 1999, at a depth of 5–10 m. A voucher specimen (No. S-99-3) was deposited at the Tokyo University of Pharmacy and Life Science, Tokyo, Japan. Wet specimens (706 g) were immersed in MeOH (3 \times 2 l). After filtration, MeOH was removed under reduced pressure. The MeOH extract (47.5 g) was partitioned between hexane and H_2O , and the hexane layer was concentrated under reduced pressure to give a hexane-soluble portion (11.4 g). Most of the hexane-soluble portion (11.3 g) was chromatographed on an ODS column (200 g). Stepwise elution with MeOH- H_2O (9:1 for five fractions, 19:1 for two fractions, 200 ml of each) and MeOH (400 ml) gave eight fractions. The fifth fraction (1.23 g) [eluted with MeOH- H_2O (9:1)] containing sesquiterpenoids and the final fraction (1.20 g) containing sterols were obtained. Each fraction was subjected to normal-phase silica gel flash column chromatography, followed by MPLC separation to obtain almost pure **1** and **2**, respectively. Further purification was carried out with recycled HPLC to afford **1** [11.8 mg, using a normal-phase column, hexane-2-propanol (20:1)] and **2** [13.4 mg, using a reverse-phase column, MeOH- H_2O (19:1)]. Axinysterol (**3**, 339 mg) and some sesquiterpenoids possessing a bisabolane skeleton were also obtained in this separation.

(*E*)-3-Isocyanobisabolane-7,10-diene (**1**): Colorless oil. $[\alpha]_D^{25}$ 0.0° ($c=0.75$, CHCl_3). IR (dry film) ν_{max} cm^{-1} : 2130. ^1H - and ^{13}C -NMR, see Table 1. HR-EI-MS m/z : 230.1912 (Calcd for $\text{C}_{16}\text{H}_{25}\text{N}$: 230.1909 $[\text{M}-\text{H}]^+$).

9(11)-Dehydroaxinysterol (**2**): White amorphous solid. $[\alpha]_D^{25}$ +78.9° ($c=0.89$, CHCl_3). IR (dry film) ν_{max} cm^{-1} : 3389, 2962, 1644. ^1H - and ^{13}C -NMR, see Table 2. HR-EI-MS m/z : 424.2971 (Calcd for $\text{C}_{28}\text{H}_{40}\text{O}_3$: 424.2977 $[\text{M}]^+$).

Catalytic Hydrogenation of 2 to 4 A mixture of **2** (0.6 mg) and 10% palladium on charcoal (2 mg) in ethyl acetate (0.5 ml) was vigorously stirred under a hydrogen atmosphere at room temperature for 3.5 h. The mixture was filtered through a short Celite column, rinsed with ethyl acetate, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography [hexane–ethyl acetate (3 : 1)] and HPLC [hexane–2-propanol (9 : 1)] to obtain diol **4** (0.6 mg, 100% yield) as a white solid. $[\alpha]_D^{25} + 13.3^\circ$ ($c=0.06$, CHCl_3).¹¹ IR (dry film) ν_{max} cm^{-1} : 3406, 3311, 2926. ¹H-NMR (400 MHz, CDCl_3) δ ppm: 0.62 (3H, s, H-18), 0.78 (3H, d, $J=6.8$ Hz, H-27), 0.79 (3H, d, $J=6.8$ Hz, H-26), 0.83 (3H, d, $J=6.9$ Hz, H-28), 0.94 (3H, d, $J=6.5$ Hz, H-21), 1.13 (3H, s, H-19), 4.12 (1H, tt, $J=5.2, 10.6$ Hz, H-3). ¹³C-NMR (100 MHz, CDCl_3) δ ppm: 11.0, 15.5, 17.6, 18.9, 20.5, 23.1, 23.3, 23.4, 23.5, 28.7, 29.5, 29.7, 30.7, 31.0, 31.5, 33.7, 36.7, 36.7, 39.1, 40.8, 41.9, 42.1, 51.6, 54.6, 67.2, 74.3, 129.5, 132.8. HR-EI-MS m/z : 398.3534 (Calcd for $\text{C}_{28}\text{H}_{46}\text{O}$: 398.3549 [$\text{M}-\text{H}_2\text{O}$]⁺).

Preparation of 4 from Ergosterol The oxidation reaction was carried out according to the procedure described in the literature.^{5,12} The mixture of products was separated by silica gel flash column chromatography [hexane–ethyl acetate (4 : 1)], followed by MPLC separation [reverse phase, $\text{MeOH}-\text{H}_2\text{O}$ (9 : 1)] to afford 9(11)-dehydro-5 α ,8 α -epidioxyergosterol (**5**, 25 mg, 12% yield) as a faint yellow solid. A mixture of **5** (4.9 mg) and 10% palladium on charcoal (5 mg) in ethyl acetate (3 ml) was vigorously stirred under a hydrogen atmosphere at room temperature for 3 h. The mixture was filtered through a short Celite column, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography [hexane–ethyl acetate (1 : 1)], followed by HPLC separation [normal phase, hexane–2-propanol (9 : 1)] to obtain diol **4** (2.8 mg, 59% yield) as a white solid. $[\alpha]_D^{25} + 10.6^\circ$ ($c=0.11$, CHCl_3). The spectral data of **4** prepared by this method were identical to those of **4** from natural **2**.

Acknowledgments The authors thank Dr. Y. Shida at the Tokyo Univer-

sity of Pharmacy and Life Science for measurement of mass spectra.

References and Notes

- 1) Present address: *Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan.*
- 2) Iwashima M., Terada I., Okamoto K., Iguchi K., *J. Org. Chem.*, **67**, 2977–2981 (2002).
- 3) Watanabe K., Tsuda Y., Iwashima M., Iguchi K., *J. Nat. Prod.*, **63**, 258–260 (2000).
- 4) Iwashima M., Nara K., Nakamichi Y., Iguchi K., *Steroids*, **66**, 25–32 (2001).
- 5) Iguchi K., Shimura H., Yang Z., Yamada Y., *Steroids*, **58**, 410–413 (1993).
- 6) Meyer B. N., Ferrigni N. R., Putnam J. E., Jacobsen L. B., Nichols D. E., McLaughlin J. L., *Planta Med.*, **45**, 31–34 (1982).
- 7) Yamori T., Matsunaga A., Sato A., Yamazaki K., Komi A., Ishizu K., Mita I., Edatsugi H., Matsuba Y., Takezawa K., Nakanishi O., Kohno H., Nakajima Y., Komatsu H., Andoh T., Tsuruo T., *Cancer Res.*, **59**, 4042–4049 (1999).
- 8) Gulavita N. K., de Siva E. D., Hagadone M. R., Karuso P., Scheuer P. J., *J. Org. Chem.*, **51**, 5136–5139 (1986).
- 9) Kassuhlka K. E., Potts B. C. M., Faulkner D. J., *J. Org. Chem.*, **56**, 3747–3750 (1991) and references cited therein.
- 10) Sullivan B. W., Faulkner D. J., Okamoto K. T., Chen M. H. M., Clardy J., *J. Org. Chem.*, **51**, 5134–5136 (1986).
- 11) Hallsworth A. S., Henbest H. B., Wrigley T. I., *J. Chem. Soc.*, **1957**, 1969–1981 (1957). This paper described the optical rotation of **4** as $[\alpha]_D + 34^\circ$ without any information about either the concentration or the solvent.
- 12) Windaus A., Brunken J., *Ann. Chem.*, **460**, 225–235 (1928).